

Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Source Type (Chimeric, Murine, Humanized, Human), By Production Type (In Vivo, In Vitro), By Application, By End-use, By Region, And Segment Forecasts, 2022 - 2030

https://marketpublishers.com/r/M0473732D7CEN.html

Date: August 2022

Pages: 120

Price: US\$ 5,950.00 (Single User License)

ID: M0473732D7CEN

Abstracts

This report can be delivered to the clients within 3 Business Days

Monoclonal Antibodies Market Growth & Trends

The global monoclonal antibodies market is projected to reach USD 494.53 billion by 2030, at a compound annual growth rate (CAGR) of 11.30% in the forecast period, according to a new report by Grand View Research, Inc. Increasing research and development activities aimed at the development of novel therapeutic monoclonal antibodies (mAbs) and supportive government initiatives for biologics production are anticipated to drive the market growth in the forecast period.

The rising demand for personalized medicine is likely to positively affect the development of therapeutic mAb targeted therapies that are tailored to individual requirements. Moreover, the therapeutic use of mAbs offers several advantages such as fewer adverse effects, specificity of treatment, and large-scale production capabilities, as compared to conventional treatment options, and can significantly drive market growth.

In addition, several government entities are fueling clinical research activities and expanding the scope of applications for mAb therapies. For instance, in June 2022, the National Institutes of Health launched clinical trials for the evaluation of dupilumab, for the reduction of asthma attacks and the improvement of lung functionality in children.



Similarly, in March 2021, the U.S. Department of Health and Human Services invested USD 150 million in increasing patient access to monoclonal antibody therapeutics for COVID-19. Such initiatives are expected to increase the adoption of monoclonal antibodies and strengthen the growth prospects.

Furthermore, technological advancements in genetic engineering, DNA cloning, and various peptide and protein display technologies have led to the generation and optimization of recombinant mAbs. Demand for such recombinant antibodies is driven by increasing commercial prospects and quality requirements that may not be fulfilled by hybridoma technologies. Hence, with the increasing commercial viability of recombinant technologies, the market is expected to witness significant growth.

The COVID-19 pandemic has created several market expansion opportunities by fueling the development of several mAbs directed against the SARS-CoV-2 virus. As mAbs represent a promising alternative for mitigation of the disease due to their safety and effectiveness, several mAbs such as Eli Lilly's bebtelovimab, and GlaxoSmithKline & Vir Biotechnology's sotrovimab have attained emergency use authorizations from the U.S. FDA. Such authorizations are likely to broaden the horizons for the growth of mAbs applications and propel market growth.

Monoclonal Antibodies Market Report Highlights

By source type, the human mAbs segment held the largest share of 54.07% in 2021 due to the low immunogenicity offered and increasing cancer treatment applications of these antibodies

In vitro production type held a dominating share of 78.45% in 2021 due to the low contamination levels offered by the technique and the availability of advanced bio-manufacturing capabilities

The oncology segment dominated the market in 2021 due to the rising number of approvals for mAb cancer therapeutics and increasing scientific and patient awareness about such therapies

Hospitals accounted for the largest share of the end-use segment in 2021 due to the widespread use of mAbs for cancer treatment in hospitals and increasing healthcare expenditure favoring the adoption of such therapeutics

North America accounted for 46.2% of the market value in 2021 due to the



availability of advanced healthcare infrastructure, high growth in cancer incidence, and local presence of key players such as Pfizer Inc., Amgen, Inc., and Merck & Co., among others

The Asia Pacific is projected to witness the highest growth rate in the forecast period due to the availability of a large patient pool for cancer treatment and expanding the scope of clinical research prospects for mAbs.



Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market Segmentation
 - 1.1.1 Estimates And Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
 - 1.3.1 Purchased Database
 - 1.3.2 Gvr's Internal Database
 - 1.3.3 Secondary Source Types
 - 1.3.4 Primary Research
 - 1.3.5 Details Of Primary Research
- 1.4 Information Or Data Analysis
 - 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
 - 1.6.1 Commodity Flow Analysis
 - 1.6.1.1 Approach 1: Commodity flow approach
 - 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
- 1.7 Global Market: CAGR Calculation
- 1.8 Research Assumptions
- 1.9 List of Secondary Source types
- 1.10 List of Primary Source types
- 1.11 Objectives
 - 1.11.1 Objective 1:
 - 1.11.2 Objective 2:
- 1.12 List Of Abbreviations

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Market Outlook
- 2.2 Market Summary

CHAPTER 3 MONOCLONAL ANTIBODIES MARKET VARIABLES, TRENDS & SCOPE

- 3.1 Market Trends & Outlook
- 3.2 Market Segmentation & Scope



- 3.3 Market Driver Analysis
 - 3.3.1 Increasing Incidences Of Chronic Diseases
 - 3.3.2 Technological Advancements
 - 3.3.3 Growing Awareness Levels
- 3.4 Market Restraint Analysis
 - 3.4.1 High Cost Of Therapeutic Mabs
- 3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
- 3.6 Porter's Five Forces Analysis
- 3.7 COVID-19 Impact Analysis
- 3.8 Penetration & Growth Prospect Mapping

CHAPTER 4 MONOCLONAL ANTIBODIES MARKET - SEGMENT ANALYSIS, BY SOURCE TYPE, 2018 - 2030 (USD BILLION)

- 4.1 Monoclonal Antibodies Market: Source Type Movement Analysis
- 4.2 Murine
 - 4.2.1 Murine Market Estimates And Forecast, 2018 2030 (USD Billion)
- 4.3 Chimeric
 - 4.3.1 Chimeric Market Estimates And Forecast, 2018 2030 (USD Billion)
- 4.4 Humanized
 - 4.4.1 Humanized Market Estimates And Forecast, 2018 2030 (USD Billion)
- 4.5 Human
 - 4.5.1 Human Market Estimates And Forecast, 2018 2030 (USD Billion)

CHAPTER 5 MONOCLONAL ANTIBODIES MARKET - SEGMENT ANALYSIS, BY PRODUCTION TYPE, 2018 - 2030 (USD BILLION)

- 5.1 Monoclonal Antibodies Market: Production Type Movement Analysis
- 5.2 In Vivo
 - 5.2.1 In Vivo Market Estimates And Forecast, 2018 2030 (USD Billion)
- 5.3 In Vitro
 - 5.3.1 In Vitro Market Estimates And Forecast, 2018 2030 (USD Billion)

CHAPTER 6 MONOCLONAL ANTIBODIES MARKET - SEGMENT ANALYSIS, BY APPLICATION, 2018 - 2030 (USD BILLION)

- 6.1 Monoclonal Antibodies Market: Application Movement Analysis
- 6.2 Oncology
 - 6.2.1 Oncology Market Estimates And Forecast, 2018 2030 (USD Billion)



- 6.3 Autoimmune Diseases
- 6.3.1 Autoimmune Diseases Market Estimates And Forecast, 2018 2030 (USD Billion)
- 6.4 Infectious Diseases
 - 6.4.1 Infectious Diseases Market Estimates And Forecast, 2018 2030 (USD Billion)
- 6.5 Neuological Diseases
- 6.5.1 Neurological Diseases Market Estimates And Forecast, 2018 2030 (USD Billion)
- 6.6 Others
 - 6.6.1 Other Applications Market Estimates And Forecast, 2018 2030 (USD Billion)

CHAPTER 7 MONOCLONAL ANTIBODIES MARKET - SEGMENT ANALYSIS, BY END-USE, 2018 - 2030 (USD BILLION)

- 7.1 Monoclonal Antibodies Market: End-Use Movement Analysis
- 7.2 Hospitals
- 7.2.1 Hospitals Market Estimates And Forecast, 2018 2030 (USD Billion)
- 7.3 Specialty Centers
- 7.3.1 Specialty Centers Market Estimates And Forecast, 2018 2030 (USD Billion)
- 7.4 Others
 - 7.4.1 Other End-Use Market Estimates And Forecast, 2018 2030 (USD Billion)

CHAPTER 8 MONOCLONAL ANTIBODIES MARKET - SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD BILLION)

- 8.1 Monoclonal Antibodies Market: Regional Movement Analysis
- 8.2 North America
 - 8.2.1 North America Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.2.2 U.S.
 - 8.2.2.1 U.S. Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.2.3 Canada
 - 8.2.3.1 Canada Market Estimates And Forecast, 2018 2030 (USD Billion)
- 8.3 Europe
 - 8.3.1 Europe Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.3.2 Uk
 - 8.3.2.1 Uk Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.3.3 Germany
 - 8.3.3.1 Germany Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.3.4 France



- 8.3.4.1 France Market Estimates And Forecast, 2018 2030 (USD Billion)
- 8.3.5 Italy
 - 8.3.5.1 Italy Market Estimates And Forecast, 2018 2030 (USD Billion)
- 8.3.6 Spain
- 8.3.6.1 Spain Market Estimates And Forecast, 2018 2030 (USD Billion)
- 8.4 Asia Pacific
 - 8.4.1 Asia Pacific Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.4.2 Japan
 - 8.4.2.1 Japan Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.4.3 China
 - 8.4.3.1 China Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.4.4 India
 - 8.4.4.1 India Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.4.5 Australia
 - 8.4.5.1 Australia Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.4.6 South Korea
 - 8.4.6.1 South Korea Market Estimates And Forecast, 2018 2030 (USD Billion)
- 8.5 Latin America
 - 8.5.1 Latin America Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.5.2 Brazil
 - 8.5.2.1 Brazil Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.5.3 Mexico
 - 8.5.3.1 Mexico market estimates and forecast, 2018 2030 (USD Billion)
- 8.6 Middle East and Africa
- 8.6.1 Middle-East And Africa Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.6.2 South Africa
 - 8.6.2.1 South Africa Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.6.3 Saudi Arabia
 - 8.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 2030 (USD Billion)
 - 8.6.4 Uae
 - 8.6.4.1 Uae Market Estimates And Forecast, 2018 2030 (USD Billion)

CHAPTER 9 COMPETITIVE ANALYSIS

- 9.1 Strategy Framework
- 9.2 Company/Competition Categorization
- 9.3 Company Profiles
 - 9.3.1 NOVARTIS AG



- 9.3.1.1 Company Overview
- 9.3.1.2 Financial Performance
- 9.3.1.3 Product Benchmarking
- 9.3.1.4 Strategic Initiatives
- 9.3.2 PFIZER INC
 - 9.3.2.1 Company Overview
 - 9.3.2.2 Financial Performance
 - 9.3.2.3 Product Benchmarking
 - 9.3.2.4 Strategic Initiatives
- 9.3.3 AMGEN INC.
 - 9.3.3.1 Company Overview
 - 9.3.3.2 Financial Performance
 - 9.3.3.3 Product Benchmarking
 - 9.3.3.4 Strategic Initiatives
- 9.3.4 GlaxoSmithKline plc
 - 9.3.4.1 Company Overview
 - 9.3.4.2 Financial Performance
 - 9.3.4.3 Product Benchmarking
 - 9.3.4.4 Strategic Initiatives
 - 9.3.3.4 Strategic Initiatives
- 9.3.5 MERCK & CO., INC.
 - 9.3.5.1 Company Overview
 - 9.3.5.2 Financial Performance
 - 9.3.5.3 Product Benchmarking
 - 9.3.5.4 Strategic Initiatives
- 9.3.6 DAIICHI SANKYO COMPANY, LIMITED
 - 9.3.6.1 Company Overview
 - 9.3.6.2 Financial Performance
 - 9.3.6.3 Product Benchmarking
 - 9.3.6.4 Strategic Initiatives
- 9.3.7 ABBOTT LABORATORIES
 - 9.3.7.1 Company Overview
 - 9.3.7.2 Financial Performance
 - 9.3.7.3 Product Benchmarking
 - 9.3.7.4 Strategic Initiatives
- 9.3.8 ASTRAZENECA PLC
 - 9.3.8.1 Company Overview
 - 9.3.8.2 Financial Performance
 - 9.3.8.3 Product Benchmarking



- 9.3.8.4 Strategic Initiatives
- 9.3.9 ELI LILLY AND COMPANY
 - 9.3.9.1 Company Overview
 - 9.3.9.2 Financial Performance
 - 9.3.9.3 Product Benchmarking
- 9.3.9.4 Strategic Initiatives
- 9.3.10 JOHNSON & JOHNSON SERVICES, INC.
 - 9.3.10.1 Company Overview
 - 9.3.10.2 Financial Performance
 - 9.3.10.3 Product Benchmarking
 - 9.3.10.4 Strategic Initiatives
- 9.3.11 BAYER AG
 - 9.3.11.1 Company Overview
 - 9.3.11.2 Financial Performance
 - 9.3.11.3 Product Benchmarking
 - 9.3.11.4 Strategic Initiatives
- 9.3.12 BRISTOL MYERS SQUIBB
 - 9.3.12.1 Company Overview
 - 9.3.12.2 Financial Performance
 - 9.3.12.3 Product Benchmarking
 - 9.3.12.4 Strategic Initiatives
- 9.3.13 F. HOFFMAN-LA ROCHE LTD.
 - 9.3.13.1 Company Overview
 - 9.3.13.2 Financial Performance
 - 9.3.13.3 Product Benchmarking
 - 9.3.13.4 Strategic Initiatives
- 9.3.14 VIATRIS INC.
 - 9.3.14.1 Company Overview
 - 9.3.14.2 Financial Performance
 - 9.3.14.3 Product Benchmarking
 - 9.3.14.4 Strategic Initiatives
- 9.3.15 BIOGEN INC.
 - 9.3.15.1 Company Overview
 - 9.3.15.2 Financial Performance
 - 9.3.15.3 Product Benchmarking
 - 9.3.15.4 Strategic Initiatives
- 9.3.16 THERMO FISHER SCIENTIFIC, INC.
 - 9.3.16.1 Company Overview
 - 9.3.16.2 Financial Performance



- 9.3.16.3 Product Benchmarking
- 9.3.16.4 Strategic Initiatives
- 9.3.17 NOVO NORDISK A/S
 - 9.3.17.1 Company Overview
 - 9.3.17.2 Financial Performance
 - 9.3.17.3 Product Benchmarking
 - 9.3.17.4 Strategic Initiatives
- 9.3.18 SANOFI S.A.
 - 9.3.18.1 Company Overview
 - 9.3.18.2 Financial Performance
 - 9.3.18.3 Product Benchmarking
 - 9.3.18.4 Strategic Initiatives
- 9.3.19 MERCK KGAA
 - 9.3.19.1 Company Overview
 - 9.3.19.2 Financial Performance
 - 9.3.19.3 Product Benchmarking
 - 9.3.19.4 Strategic Initiatives



List Of Tables

LIST OF TABLES

- Table 1 Global monoclonal antibodies market, by region, 2018 2030 (USD Billion)
- Table 2 Global monoclonal antibodies market, by source type, 2018 2030 (USD Billion)
- Table 3 Global monoclonal antibodies market, by production type, 2018 2030 (USD Billion)
- Table 4 Global monoclonal antibodies market, by application, 2018 2030 (USD Billion)
- Table 5 Global monoclonal antibodies market, by end-use, 2018 2030 (USD Billion)
- Table 6 North America monoclonal antibodies market, by source type, 2018 2030 (USD Billion)
- Table 7 North America monoclonal antibodies market, by production type, 2018 2030 (USD Billion)
- Table 8 North America monoclonal antibodies market, by application, 2018 2030 (USD Billion)
- Table 9 North America monoclonal antibodies market, by end-use, 2018 2030 (USD Billion)
- Table 10 U.S. monoclonal antibodies market, by source type, 2018 2030 (USD Billion)
- Table 11 U.S. monoclonal antibodies market, by production type, 2018 2030 (USD Billion)
- Table 12 U.S. monoclonal antibodies market, by application, 2018 2030 (USD Billion)
- Table 13 U.S. monoclonal antibodies market, by end-use, 2018 2030 (USD Billion)
- Table 14 Canada monoclonal antibodies market, by source type, 2018 2030 (USD Billion)
- Table 15 Canada monoclonal antibodies market, by production type, 2018 2030 (USD Billion)
- Table 16 Canada monoclonal antibodies market, by application, 2018 2030 (USD Billion)
- Table 17 Canada monoclonal antibodies market, by end-use, 2018 2030 (USD Billion)
- Table 18 Europe monoclonal antibodies market, by source type, 2018 2030 (USD Billion)
- Table 19 Europe monoclonal antibodies market, by production type, 2018 2030 (USD Billion)
- Table 20 Europe monoclonal antibodies market, by application, 2018 2030 (USD Billion)
- Table 21 Europe monoclonal antibodies market, by end-use, 2018 2030 (USD Billion)
- Table 22 UK monoclonal antibodies market, by source type, 2018 2030 (USD Billion).



- Table 23 UK monoclonal antibodies market, by production type, 2018 2030 (USD Billion)
- Table 24 UK monoclonal antibodies market, by application, 2018 2030 (USD Billion)
- Table 25 UK monoclonal antibodies market, by end-use, 2018 2030 (USD Billion)
- Table 26 Germany monoclonal antibodies market, by source type, 2018 2030 (USD Billion)
- Table 27 Germany monoclonal antibodies market, by production type, 2018 2030 (USD Billion)
- Table 28 Germany monoclonal antibodies market, by application, 2018 2030 (USD Billion)
- Table 29 Germany monoclonal antibodies market, by end-use, 2018 2030 (USD Billion)
- Table 30 France monoclonal antibodies market, by source type, 2018 2030 (USD Billion)
- Table 31 France monoclonal antibodies market, by production type, 2018 2030 (USD Billion)
- Table 32 France monoclonal antibodies market, by application, 2018 2030 (USD Billion)
- Table 33 France monoclonal antibodies market, by end-use, 2018 2030 (USD Billion)
- Table 34 Italy monoclonal antibodies market, by source type, 2018 2030 (USD Billion)
- Table 35 Italy monoclonal antibodies market, by production type, 2018 2030 (USD Billion)
- Table 36 Italy monoclonal antibodies market, by application, 2018 2030 (USD Billion)
- Table 37 Italy monoclonal antibodies market, by end-use, 2018 2030 (USD Billion)
- Table 38 Spain monoclonal antibodies market, by source type, 2018 2030 (USD Billion)
- Table 39 Spain monoclonal antibodies market, by production type, 2018 2030 (USD Billion)
- Table 40 Spain monoclonal antibodies market, by application, 2018 2030 (USD Billion)
- Table 41 Spain monoclonal antibodies market, by end-use, 2018 2030 (USD Billion)
- Table 42 Asia Pacific monoclonal antibodies market, by source type, 2018 2030 (USD Billion)
- Table 43 Asia Pacific monoclonal antibodies market, by production type, 2018 2030 (USD Billion)
- Table 44 Asia Pacific monoclonal antibodies market, by application, 2018 2030 (USD Billion)
- Table 45 Asia Pacific monoclonal antibodies market, by end-use, 2018 2030 (USD Billion)
- Table 46 Japan monoclonal antibodies market, by source type, 2018 2030 (USD



Billion)

Table 47 Japan monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)

Table 48 Japan monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)

Table 49 Japan monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)

Table 50 China monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)

Table 51 China monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)

Table 52 China monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)

Table 53 China monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)

Table 54 India monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)

Table 55 India monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)

Table 56 India monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)

Table 57 India monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)

Table 58 Australia monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)

Table 59 Australia monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)

Table 60 Australia monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)

Table 61 Australia monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)

Table 62 South Korea monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)

Table 63 South Korea monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)

Table 64 South Korea monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)

Table 65 South Korea monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)

Table 66 Latin America monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)

Table 67 Latin America monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)

Table 68 Latin America monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)



Table 69 Latin America monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)

Table 70 Brazil monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)

Table 71 Brazil monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)

Table 72 Brazil monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)

Table 73 Brazil monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)

Table 74 Mexico monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)

Table 75 Mexico monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)

Table 76 Mexico monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)

Table 77 Mexico monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)

Table 78 Middle East & Africa monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)

Table 79 Middle East & Africa monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)

Table 80 Middle East & Africa monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)

Table 81 Middle East & Africa monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)

Table 82 South Africa monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)

Table 83 South Africa monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)

Table 84 South Africa monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)

Table 85 South Africa monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)

Table 86 Saudi Arabia monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)

Table 87 Saudi Arabia monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)

Table 88 Saudi Arabia monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)

Table 89 Saudi Arabia monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)



Table 90 UAE monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion) Table 91 UAE monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)

Table 92 UAE monoclonal antibodies market, by application, 2018 - 2030 (USD Billion) Table 93 UAE monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)



List Of Figures

LIST OF FIGURES

- Figure 2 Information procurement
- Figure 3 Primary research pattern
- Figure 4 Market research approaches
- Figure 5 Value chain-based sizing & forecasting
- Figure 6 Market formulation & validation
- Figure 7 Monoclonal antibodies market segmentation
- Figure 8 Market driver relevance analysis (current & future impact)
- Figure 9 Market restraint relevance analysis (current & future impact)
- Figure 10 Penetration & growth prospect mapping
- Figure 11 SWOT analysis, by factor (political & legal, economic and technological)
- Figure 12 Porter's five forces analysis
- Figure 13 Market penetration vs growth prospect mapping
- Figure 14 Monoclonal antibodies market: Source type outlook and key takeaways
- Figure 15 Monoclonal antibodies market: Source type movement analysis
- Figure 16 Murine market, 2018 2030 (USD Billion)
- Figure 17 Chimeric market, 2018 2030 (USD Billion)
- Figure 18 Humanized market, 2018 2030 (USD Billion)
- Figure 19 Human market, 2018 2030 (USD Billion)
- Figure 20 Monoclonal antibodies market: Production type outlook and key takeaways
- Figure 21 Monoclonal antibodies market: Production type movement analysis
- Figure 22 In vivo market, 2018 2030 (USD Billion)
- Figure 23 In vitro market, 2018 2030 (USD Billion)
- Figure 24 Monoclonal antibodies market: Application outlook and key takeaways
- Figure 25 Monoclonal antibodies market: Application movement analysis
- Figure 26 Oncology market, 2018 2030 (USD Billion)
- Figure 27 Autoimmune diseases market, 2018 2030 (USD Billion)
- Figure 28 Infectious diseases market, 2018 2030 (USD Billion)
- Figure 29 Neurological diseases market, 2018 2030 (USD Billion)
- Figure 30 Other applications, 2018 2030 (USD Billion)
- Figure 31 Monoclonal antibodies market: End-use outlook and key takeaways
- Figure 32 Monoclonal antibodies market: End-use movement analysis
- Figure 33 Hospitals market, 2018 2030 (USD Billion)
- Figure 34 Specialty centres, 2018 2030 (USD Billion)
- Figure 35 Other end-use market, 2018 2030 (USD Billion)



Figure 36 Regional market: Key takeaways

Figure 37 Regional outlook, 2018 & 2030

Figure 38 North America monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 39 U.S. monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 40 Canada monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 41 Europe monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 42 UK monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 43 Germany monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 44 France monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 45 Italy monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 46 Spain monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 47 Asia Pacific monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 48 Japan monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 49 China monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 50 India monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 51 Australia monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 52 South Korea monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 53 Latin America monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 54 Brazil monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 55 Mexico monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 56 MEA monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 57 South Africa monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 58 Saudi Arabia monoclonal antibodies market, 2018 - 2030 (USD Billion)

Figure 59 UAE monoclonal antibodies market, 2018 - 2030 (USD Billion)



I would like to order

Product name: Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Source Type

(Chimeric, Murine, Humanized, Human), By Production Type (In Vivo, In Vitro), By

Application, By End-use, By Region, And Segment Forecasts, 2022 - 2030

Product link: https://marketpublishers.com/r/M0473732D7CEN.html

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/M0473732D7CEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970